Scholarlink

<p> To examine the short-term therapeutic effects of Bioptron light therapy (BLT) on dry eye disease (DED) in postmenopausal women.&#xa0;Sixty postmenopausal women diagnosed with DED, aged 50–62 years with a body mass index ≤ 30&#xa0;kg/m², were randomly assigned to two equal groups. The Bioptron group (<i>n</i> = 30) received BLT for 10&#xa0;min, twice weekly, along with an educational program for four weeks. The control group (<i>n</i> = 30) received the same educational program only. Outcomes were measured using Schirmer’s test (Schirmer I) for basal tear secretion, Tear Break-Up Time (TBUT) for tear film stability, and the Dry Eye-related Quality of Life Score (DEQS) for quality of life (QOL).&#xa0;Both groups exhibited significant improvements post-treatment compared to pre-treatment in all variables, with greater percentage changes from baseline in the BLT group. Between-group comparisons revealed significantly higher improvements in the BLT group: Schirmer’s test (Schirmer I) improved by MD = 8.7 (95% CI: 7.64–9.76; <i>p</i> = 0.001), TBUT by MD = 2.97 (95% CI: 1.7–4.3; <i>p</i> = 0.007), and DEQS decreased by MD = − 24.1 (95% CI: −37 to − 17.1; <i>p</i> = 0.002). Compared with standardized education alone, adjunctive Bioptron light therapy significantly enhanced tear secretion, tear film stability, and patient-reported symptoms, suggesting its potential as an effective non-pharmacological option for managing dry eye in postmenopausal women. The trial was registered at Clinical Trials.gov (Identifier: NCT05964673)</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effect of Bioptron light therapy on dryness of eyes in postmenopausal women: a randomized controlled trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月4日

查看全文
  • Ehab Mohamed Elsayed Saad,
  • Sara Magdy Ahmed,
  • Amel Mohamed Yousef,
  • Elham Shahat Hassan

摘要

To examine the short-term therapeutic effects of Bioptron light therapy (BLT) on dry eye disease (DED) in postmenopausal women. Sixty postmenopausal women diagnosed with DED, aged 50–62 years with a body mass index ≤ 30 kg/m², were randomly assigned to two equal groups. The Bioptron group (n = 30) received BLT for 10 min, twice weekly, along with an educational program for four weeks. The control group (n = 30) received the same educational program only. Outcomes were measured using Schirmer’s test (Schirmer I) for basal tear secretion, Tear Break-Up Time (TBUT) for tear film stability, and the Dry Eye-related Quality of Life Score (DEQS) for quality of life (QOL). Both groups exhibited significant improvements post-treatment compared to pre-treatment in all variables, with greater percentage changes from baseline in the BLT group. Between-group comparisons revealed significantly higher improvements in the BLT group: Schirmer’s test (Schirmer I) improved by MD = 8.7 (95% CI: 7.64–9.76; p = 0.001), TBUT by MD = 2.97 (95% CI: 1.7–4.3; p = 0.007), and DEQS decreased by MD = − 24.1 (95% CI: −37 to − 17.1; p = 0.002). Compared with standardized education alone, adjunctive Bioptron light therapy significantly enhanced tear secretion, tear film stability, and patient-reported symptoms, suggesting its potential as an effective non-pharmacological option for managing dry eye in postmenopausal women. The trial was registered at Clinical Trials.gov (Identifier: NCT05964673)